Viewray (NASDAQ:VRAY) issued its quarterly earnings data on Monday. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.17), Briefing.com reports. The business had revenue of $19.90 million during the quarter, compared to analysts’ expectations of $21.23 million. The company’s revenue for the quarter was up 23.6% compared to the same quarter last year.
Shares of Viewray (NASDAQ:VRAY) opened at $7.95 on Tuesday. The firm has a market capitalization of $591.17, a price-to-earnings ratio of -7.29 and a beta of 15.29. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67. Viewray has a 1 year low of $4.40 and a 1 year high of $10.64.
Several large investors have recently added to or reduced their stakes in VRAY. Nationwide Fund Advisors lifted its position in shares of Viewray by 843.2% during the 2nd quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after acquiring an additional 14,789 shares during the period. PEAK6 Investments L.P. bought a new stake in shares of Viewray during the 4th quarter valued at $148,000. MetLife Investment Advisors LLC bought a new stake in shares of Viewray during the 4th quarter worth $148,000. The Manufacturers Life Insurance Company bought a new stake in shares of Viewray during the 2nd quarter worth $159,000. Finally, Thompson Siegel & Walmsley LLC bought a new stake in shares of Viewray during the 3rd quarter worth $164,000. Hedge funds and other institutional investors own 63.22% of the company’s stock.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.